RESUMO
Seven new drugs innovated in China were acquired by multinational pharmaceutical companies in 2013,most of which were in pre-clinical or clinical research stage. This reflects that the current R&D capabilities of drug innovation in China have gradually caught up with the international standards and have been internationally recognized. On the other hand,it shows that there is still a big gap in the overall competitiveness of the pharmaceutical industry between China and the international counterparts. Some suggestions are proposed,including the cultivation of the leading pharmaceutical companies,the appropriate subsidies to domestic enterprises for new drug transformation,the improvement for personnel training and the supports to the small and medium enterprises.